Biotech industry in Israel – real progress
The biotech industry in Israel seems to be finding its feet.
A week ago, “The Calcalist” – The Economist in English – daily financial paper reported on a new round of investments in the sector.
- Bonus Biogroup completed an 18 million shekel (approx US$4.7m) sale of shares, ahead of its offer in the USA.
- VBL, already present on NASDAQ, took in US$24m in order to boost its search for creating drugs against cancer.
- Micromedic’s shares shot up 140% ahead of an announcement relating the success of its diagnostic kit for cancer.
- Kitov raised US$12m on results that show its main product is highly effective in combatting arthritis.
These are not isolated pieces of news. At the end of June 2016, the Israel Biotech Fund (IBF) made its first move, selecting cancer drug developer “Vidac” as its first partner. IBF has a US$100m treasure chest to spend, supported by American giant Biogen, Medison, and others.
On a micro level, BioJerusalem and JBNF-Bio have had major success in recent years partnering local start ups with multinationals. The latter recently held a meet up with nearly 100 participants on how to create a start up. The bug of entrepreneurship is still mutating with vigour.
At a time when much of Israel’s economy is facing a slowdown, it is refreshing to observe how biotech in the Holy Land is bucking the trend.
0 comments